NATURE: Large-scale screening, new drugs used to combat SARS-CoV-2.

!---- the emergence of the new coronavirus (SARS-CoV-2) in 2019 triggered a sustained global pandemic of severe pneumonia-like diseases, named COVID-19.vaccine development is likely to take at least 12-18 months, while the typical approval time for new antiviral therapies is likely to be more than 10 years.by contrast, the reuse of known drugs can significantly accelerate the development of new therapies for COVID-19.to do so, the researchers evaluated a known drug library containing about 12,000 clinically or FDA-approved small molecules.it reported the identification of 100 molecules that inhibit viral replication, including 21 known drugs that exhibit dose-response relationships., the researchers found that 13 molecules showed effective concentrations that might be commensurate with the therapeutic dose that patients could achieve, including piKfyve kinase inhibitor apilimod, and cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334.noteworthy, MDL-28170, ONO 5334, and apilimod were found to be able to replicate antivirals in human iPSC-derived lung cell-like cells, and PIKfyve inhibitors also exhibited antiviral efficacy in primary human lung transplantmodels.Since most of the molecules found in this study have entered the clinic, these compounds have known pharmacological and human safety characteristics that will accelerate the preclinical and clinical evaluation of these drugs for COVID-19..